UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K/A
(Amendment No. 1)
(Mark One)
☒ | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES |
For the Fiscal Year Ended December 31, 2018
OR
☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the Transition Period from to
Commission File Number: 001-37708
Syndax Pharmaceuticals, Inc.
(Exact name of Registrant as specified in its charter)
|
|
|
Delaware | 2834 | 32-0162505 |
(State or Other Jurisdiction of Incorporation or Organization) | (Primary Standard Industrial Classification Code Number) | (I.R.S. Employer Identification Number) |
35 Gatehouse Drive, Building D, Floor 3
Waltham, Massachusetts 02451
(781) 419-1400
(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)
Securities registered pursuant to Section 12(b) of the Act:
|
|
Title of Each Class
| Name of Each Exchange on Which Registered
|
Common Stock, par value $0.0001 per share | Nasdaq Global Select Market |
Securities registered pursuant to Section 12(g) of the Act: None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Act. Yes ☐ No ☒
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to the filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§ 229.405) is not contained herein, and will not be contained, to the best of the registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large Accelerated Filer | ☐ | Accelerated Filer | ☒ |
|
|
|
|
Non-accelerated Filer | ☐ | Smaller Reporting Company | ☒ |
|
|
|
|
Emerging growth company | ☒ |
|
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.) Yes ☐ No ☒
As of June 30, 2018, the last day of the registrant’s most recently completed second fiscal quarter, the aggregate market value of the Common Stock held by non-affiliates of the registrant was approximately $118.0 million, based on the closing price of the registrant’s common stock on June 30, 2018. Shares of the registrant’s common stock held by each officer and director and each person known to the registrant to own 10% or more of the outstanding common stock of the registrant have been excluded in that such persons may be deemed affiliates. This determination of affiliate status is not a determination for other purposes.
As of March 6, 2019, there were 25,000,740 shares of common stock outstanding.
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the registrant’s definitive proxy statement for its 2019 Annual Meeting of Stockholders, which the registrant intends to file pursuant to Regulation 14A with the Securities and Exchange Commission not later than 120 days after the registrant’s fiscal year ended December 31, 2018, are incorporated by reference into Part III of this Annual Report on Form 10-K.
Syndax Pharmaceuticals, Inc. (the “Company”) is filing this Amendment No. 1 to Annual Report on Form 10-K/A (this “Amendment”) to amend its Annual Report on Form 10-K for the fiscal year ended December 31, 2018 (the “Original Filing”), as originally filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 7, 2019 (the “Original Filing Date”), to update the exhibit listing in Item 15(a)(3) of Part IV of the Original Filing to incorporate by reference a previously filed exhibit that was inadvertently omitted from the exhibit list in the Original Filing.
In addition, pursuant to Rule 12b-15 under Securities Exchange Act of 1934, as amended, this Amendment also contains new certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, which are attached hereto. Because no financial statements have been amended by or included in this Amendment and this Amendment does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4 and 5 of the certifications have been omitted.
The Amendment does not amend, modify or otherwise update any other information in the Original Filing. Accordingly, this Amendment should be read in conjunction with the Original Filing. In addition, this Amendment does not reflect events that may have occurred subsequent to the Original Filing Date.
i
Item 15. Exhibits, Financial Statements and Schedules
(a)(3) Exhibits.
Exhibit |
| Description |
|
|
|
3.1 |
| |
|
|
|
3.2 |
| |
|
|
|
4.1 |
| |
|
|
|
4.2 |
| |
|
|
|
4.3 |
| |
|
|
|
4.4 |
| |
|
|
|
4.5 |
| |
|
|
|
4.6 |
| |
|
|
|
10.1* |
| |
|
|
|
10.2* |
| |
|
|
|
10.3* |
| |
|
|
|
10.4* |
| |
|
|
|
10.5* |
| |
|
|
|
1
Exhibit |
| Description |
|
|
|
| ||
|
|
|
10.7* |
| |
|
|
|
10.8* |
| |
|
|
|
10.9* |
| |
|
|
|
10.10* |
| |
|
|
|
10.11* |
| |
|
|
|
10.12* |
| |
|
|
|
10.13* |
| |
|
|
|
10.14* |
| |
|
|
|
10.15* |
| |
|
|
|
10.16* |
| |
|
|
|
10.17* |
| |
|
|
|
10.18* |
| |
|
|
|
10.19† |
| |
|
|
|
2
Exhibit |
| Description |
|
|
|
| ||
|
|
|
10.21 |
| |
|
|
|
10.22† |
| |
|
|
|
10.23† |
| |
|
|
|
10.24† |
| |
|
|
|
10.25† |
| |
|
|
|
10.26† |
| |
|
|
|
10.27† |
| |
|
|
|
10.28† |
| |
|
|
|
10.29† |
| |
|
|
|
10.30† |
| |
|
|
|
10.31† |
| |
|
|
|
3
Exhibit |
| Description |
|
|
|
| ||
|
|
|
10.33† |
| |
|
|
|
10.34† |
| |
|
|
|
10.35† |
| |
|
|
|
10.36† |
| |
|
|
|
10.37† |
| |
|
|
|
10.38† |
| |
|
|
|
10.39† |
| |
|
|
|
10.40† |
| |
|
|
|
10.41† |
| |
|
|
|
10.42† |
| |
|
|
|
10.43† |
| |
|
|
|
4
Exhibit |
| Description |
|
|
|
| ||
|
|
|
10.45† |
| |
|
|
|
10.46 |
| |
|
|
|
10.47† |
| |
|
|
|
10.48 |
| |
|
|
|
10.49 |
| |
|
|
|
21.1 |
| |
|
|
|
23.1** |
| |
|
|
|
24.1 |
| Power of Attorney (incorporated on the signature page of the Original Filing). |
|
|
|
31.1 |
| |
|
|
|
31.2 |
| |
|
|
|
32.1+** |
| |
|
|
|
101.INS** |
| XBRL Instance Document (incorporated by reference to Exhibit 101.INS to the Company’s Annual Report for the Period ended December 31, 2018 (File No. 001-37708), filed on March 7, 2019). |
|
|
|
101.SCH** |
| XBRL Taxonomy Extension Schema Document (incorporated by reference to Exhibit 101.SCH to the Company’s Annual Report for the Period ended December 31, 2018 (File No. 001-37708), filed on March 7, 2019). |
|
|
|
101.CAL** |
| XBRL Taxonomy Extension Calculation Linkbase Document (incorporated by reference to Exhibit 101.CAL to the Company’s Annual Report for the Period ended December 31, 2018 (File No. 001-37708), filed on March 7, 2019). |
|
|
|
5
Exhibit |
| Description |
|
|
|
| XBRL Taxonomy Extension Definition Linkbase Document (incorporated by reference to Exhibit 101.DEF to the Company’s Annual Report for the Period ended December 31, 2018 (File No. 001-37708), filed on March 7, 2019). | |
|
|
|
101.LAB** |
| XBRL Taxonomy Extension Label Linkbase Document (incorporated by reference to Exhibit 101.LAB to the Company’s Annual Report for the Period ended December 31, 2018 (File No. 001-37708), filed on March 7, 2019). |
|
|
|
101.PRE** |
| XBRL Taxonomy Extension Presentation Linkbase Document (incorporated by reference to Exhibit 101.PRE to the Company’s Annual Report for the Period ended December 31, 2018 (File No. 001-37708), filed on March 7, 2019). |
* | Indicates a management contract or compensatory plan. |
** | Previously filed or furnished with the registrant’s Annual Report for the Period ended December 31, 2018 (File No. 001-37708), filed on March 7, 2019. |
+ | Furnished herewith and not deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act. |
† | Confidential treatment has been granted for certain portions of this exhibit. These portions have been omitted and filed separately with the SEC. |
6
Pursuant to the requirements of Section 13 of 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Amendment No. 1 to the registrant’s Annual Report on Form 10-k/A to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
|
|
|
| SYNDAX PHARMACEUTICALS, INC. | |
|
|
|
|
Date: March 18, 2019 |
| By: | /s/ Briggs W. Morrison, M.D. |
|
|
| Briggs W. Morrison, M.D. |
|
|
| Chief Executive Officer |
7